Project Grant HT94252410636
Award Date
7/1/24
Completion Date
6/30/27
Dollars Obligated
$648K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
The University of Pittsburgh was awarded a $795,001 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The three-year award will fund a research project from September 2022 to August 2025 to interrogate the impact of B cells and tertiary lymphoid structures in melanoma brain metastases. Through this funding, the University of Pittsburgh will investigate medical solutions for the battlefield by supporting applied and advanced...
This $846,182 Project Grant award to the University of Pittsburgh was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER" with a performance period from Aug 1, 2024 to Jul 31, 2027. As a major research university, the University of Pittsburgh will leverage its extensive...
The University of Pittsburgh was awarded a $721,250 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The three-year grant will fund research on Programmed Cell Death 6 Interacting Protein (PDCD6IP) in plasma-derived exosomes as a potential prognostic biomarker of melanoma progression. Through September 2025, researchers at the University of Pittsburgh will investigate medical solutions for the...
The University of Pittsburgh was awarded a $1,572,933 federal Project Grant under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency. The grant, effective January 1, 2025 through December 31, 2028, supports advanced biomedical research aimed at "Targeting Lysosomal Pathways to Improve Host Immunity Post Coronaviral Infections." This research aligns with the program's objective to transform healthcare for military service members,...
The University of Pittsburgh has been awarded a $602,986 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, effective August 1, 2024 through August 31, 2026, will fund a research project titled "A T CELL-GUIDED APPROACH TO DEVELOP ANTIGEN-SPECIFIC IMMUNOTHERAPIES FOR PEDIATRIC BRAIN TUMORS." This project aims to develop innovative immunotherapies for treating pediatric brain tumors by leveraging the...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $346,319.00 to the University of Pittsburgh to conduct research on "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER." The award period runs from August 1, 2024 to July 31, 2027. The University of Pittsburgh, a major public research university, will leverage its expertise in...
The University of Pittsburgh received a $4,902,315 project grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on June 1, 2025, with a completion date of May 31, 2029, is funding research to understand the effects of intracavitary conditioning in breast cancer metastatic to the pleura or the peritoneum. This research aims to transform healthcare for military service members, veterans, and the broader public by...
The University of Pittsburgh received a $454,142.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "FERROPTOSIS AS A METABOLIC VULNERABILITY OF CYCLIN E-HIGH OVARIAN CANCER". This 2-year research project, with a performance period from May 2024 to May 2026, aims to investigate metabolic vulnerabilities in a specific type of ovarian cancer. The University of Pittsburgh is the primary...